TL;DR
Protocols to generate developmentally primitive and definitive RBCs from iPSCs are outlined, and methods to perform antibody identification using iPSC-derived RBCs as reagent cells in gel agglutination assays commonly used by blood banks and reference immunohematology laboratories are outlined.
This review summarizes research with a focus on clinical translation of iPSC-derived immune cells, as well as highlights continued challenges and prospects of this field.
A protocol to isolate and expand MSCs from human umbilical cord tissue and characterize their cell surface protein expression by flow cytometry, self-renewal potential by colony-forming assay, and tri-lineage differentiation capacity is outlined.
A novel strategy for generating bioengineered HLA class I-negative, "antigen-specific" megakaryocytes (MKs) from induced pluripotent stem cells (iPSCs) is described, which allows for rapid detection and characterization of platelet-specific antibodies present in patient plasma.
iPSC-derived HSPCs from patients with KD display altered immune-inflammatory transcriptional profiles and suppressed B-cell developmental signatures at the transcriptomic level, which suggest that early hematopoietic immune dysregulation may contribute to KD pathogenesis.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
